Laden…

Safer-Use-Hinweise

Atemdepression ist das primäre Überdosierungsrisiko — niemals allein anwenden ohne medizinische Aufsicht

Niemals mit Benzodiazepinen, Alkohol oder anderen ZNS-Dämpfern kombinieren — FDA Black-Box-Warnung

Naloxon-Antidot griffbereit halten, Begleiter über Anwendung informieren

Toleranz und physische Abhängigkeit entwickeln sich schnell — abruptes Absetzen vermeiden

Nach Abstinenz: stark reduzierte Toleranz — frühere Dosis kann jetzt letal sein

Orale Bioverfügbarkeit stark variabel (20–40%) — Dosisanpassung beim Wechsel von i.v. auf oral notwendig

Warnungen

⚠Respiratory depression is the primary overdose mechanism — naloxone (0.4–2 mg IV/IM/IN) reverses it rapidly; repeat dosing may be required as naloxone has shorter half-life than morphine

⚠Combining with CNS depressants (benzodiazepines, alcohol, other opioids) dramatically multiplies respiratory depression risk — responsible for majority of opioid overdose deaths

⚠Physical dependence develops with regular use over days to weeks — abrupt cessation causes withdrawal; taper gradually under medical supervision

⚠Morphine-3-glucuronide (M3G) accumulates in renal failure and causes paradoxical hyperalgesia, myoclonus, and seizures — dose reduction or opioid rotation required in renal impairment

⚠Constipation does not develop tolerance like other opioid effects — prophylactic laxatives (not fiber) should be prescribed with long-term use

⚠Always have naloxone accessible when using opioids outside supervised settings

⚠Do not crush extended-release formulations — releases full dose immediately, high overdose risk

⚠Tolerance loss occurs quickly during abstinence — resume at much lower doses after any treatment break